35187 Efficacy and safety of ruxolitinib cream for the treatment of vitiligo by patient demographics and baseline clinical characteristics: Pooled subgroup analysis from two randomized phase 3 studies

Abstract

Ruxolitinib (Janus kinase [JAK] 1/JAK2 inhibitor) cream is in development for the treatment of vitiligo, a chronic autoimmune skin disease. Two phase 3 randomized studies (TRuE-V1 [NCT04052425]; TRuE-V2 [NCT04057573]) conducted in North America and Europe enrolled patients aged ≥12 years with nonsegmental vitiligo with depigmentation covering ≤10% total body surface area (BSA). Patients (mean age, 39.6 years) were randomized 2:1 to twice-daily 1.5% ruxolitinib cream (n = 450) or vehicle (n = 224) for 24 weeks of double-blind treatment.